Bluejay Diagnostics, Inc. (NASDAQ: BJDX) reported its second-quarter 2026 financial results, disclosing that its SYMON-II pivotal clinical study has completed targeted enrollment of 750 hospital patients, according to a press release from the Acton, Mass.-based company.

The company said it is progressing toward analytical and clinical validation activities intended to support a future FDA 510(k) submission for its Symphony IL-6 test, a rapid diagnostic tool for sepsis triage. Bluejay also signed a U.S. manufacturing contract, which the company said is intended to mitigate supply-chain risk ahead of a planned commercialization effort.

At June 30, 2026, Bluejay held approximately $9.6 million in cash and cash equivalents, up from approximately $5.2 million at December 31, 2025. During the first half of 2026, the company generated approximately $7.7 million in net cash from financing activities, including approximately $7.6 million in net proceeds from a June 2026 private placement.

Neil Dey, President and Chief Executive Officer, said the company's current cash resources are estimated to fund operations through the second quarter of 2027.

The Symphony platform remains an investigational device and is limited by U.S. law to investigational use. Bluejay has not yet received regulatory clearance from the FDA to market the Symphony System as a diagnostic product in the United States.